drugset / Trial / NCT06090266
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Timeline
- Start
- 2023-10-24
- Primary completion
- 2026-08-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OR502 | Monoclonal antibody | — | Intravenous |
| Background | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |